CCM
AURA icon

CAAS Capital Management’s Aura Biosciences AURA Stock Holding History

CAAS Capital Management’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,000
Closed -$170K – 656
2021
Q4 		$170K Buy
+10,000
New +$179K ﹤0.01% 682

Other funds holding AURA

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

CAAS Capital Management's AURA Position: Q1 2022 in Review

CAAS Capital Management sold out of Aura Biosciences (AURA) in Q1 2022, closing a stake of 10,000 shares — an estimated $170K sold.

CAAS Capital Management first reported a position in AURA in Q4 2021 and held it in 1 quarter. The position peaked at $170K in Q4 2021. 34 funds tracked by Wall St. Rank hold AURA as of Q1 2022.

  • CAAS Capital Management reported no remaining Aura Biosciences position as of Q1 2022 after selling out during the quarter.
  • CAAS Capital Management sold 10,000 Aura Biosciences shares in Q1 2022, an estimated $170K.
  • CAAS Capital Management first reported a position in Aura Biosciences in Q4 2021 and held it in 1 quarter.
  • CAAS Capital Management's Aura Biosciences position peaked at $170K in Q4 2021.
  • 34 funds tracked by Wall St. Rank held Aura Biosciences as of Q1 2022.

Based on CAAS Capital Management's 13F filing for Q1 2022, filed 13 May 2022.